5 assets in Undifferentiated Carcinoma Of Nasopharynx

Therapeutic assets addressing Undifferentiated Carcinoma Of Nasopharynx, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Irinotecan Undifferentiated Carcinoma Of Nasopharynx	National Cancer Institute (NCI)	P1/2	B (60)
Ipilimumab Undifferentiated Carcinoma Of Nasopharynx	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Undifferentiated Carcinoma Of Nasopharynx	National Cancer Institute (NCI)	P2	CCC (53)
Azacitidine Undifferentiated Carcinoma Of Nasopharynx	National Cancer Institute (NCI)	P1	CC (43)
Vorinostat Undifferentiated Carcinoma Of Nasopharynx	National Cancer Institute (NCI)	P1	CC (43)